Sangamo Therapeutics draws $7 million in bankruptcy financing
SGMO•Sangamo Therapeutics reported a $14.45 million loss for August 2026 and a $7 million draw under a replacement debtor-in-possession loan facility authorized for up to $35 million. Month-end cash was $23.23 million, and the company reported a $6.73 million stockholders' equity deficit.
1. August operating report
Sangamo Therapeutics’ Chapter 11 operating report, filed October 14, showed a $14.45 million loss for August 2026, including $9.98 million in restructuring expenses. The company ended the month with $23.23 million in cash and a $6.73 million stockholders' equity deficit.
2. Financing and asset sales
Sangamo drew $7 million on August 21 under a replacement debtor-in-possession term loan facility authorized for up to $35 million. Equipment sales closed around August 20, generating $2.3 million in cash proceeds and a $250,000 offset against DIP obligations.
